Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Novo Nordisk $3.3 billion acquisition of Dicerna Pharmaceuticals
We are advising Novo Nordisk on the transaction
BDT Capital Partners acquires a majority interest in MJH Life Sciences
We are advising BDT Capital Partners on the transaction
Apria $141.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Cryoport $403 million notes offering and concurrent $249 million stock offering
The company issued 0.75% convertible senior notes due 2026 and sold shares in a registered direct offering
Aligos Therapeutics $75 million at-the-market offering
The company issued common stock in the SEC-registered at-the-market offering
Option Care Health $500 million notes offering
The company issued high-yield senior notes due 2029 in the Rule 144A / Regulation S offering
IVERIC bio $173.4 million stock offering
We advised the underwriters on the SEC-registered equity offering
MicroTech Medical HK$1.82 billion IPO
We advised MicroTech Medical on its IPO and HKEX listing